Biocartis Group NV
Develops and commercializes an automated molecular diagnostics platform for oncology.
BCART | BR
Overview
Corporate Details
- ISIN(s):
- BE0974281132 (+1 more)
- LEI:
- 549300J4HOJL5KG8HY54
- Country:
- Belgium
- Address:
- GENERAAL DE WITTELAAN 11 BOÎTE B, 2800 MECHELEN
- Website:
- https://www.biocartis.com/en
- Sector:
- Manufacturing
Description
Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-02-25 07:00 |
210224 PR_Biocartis FY20 results_ENG_FINAL.pdf
|
English | 527.8 KB | ||
| 2021-02-25 07:00 |
210224 Biocartis FY20 results_NL_FINAL.pdf
|
Dutch | 543.9 KB | ||
| 2020-12-17 07:00 |
201216 PR Outstanding shares Dec 2020_ENG_FINAL.pdf
|
English | 579.5 KB | ||
| 2020-12-17 07:00 |
201216 PR Outstanding shares Dec 2020_NL_FINAL.pdf
|
Dutch | 589.3 KB | ||
| 2020-12-07 07:00 |
Conversion convertible bonds
|
English | 163.5 KB | ||
| 2020-11-24 07:00 |
20201119 DPIF tr-1be-en_v2.pdf
|
English | 2.8 MB | ||
| 2020-11-24 07:00 |
201124_pr_transparency_debio_eng_final.pdf
|
English | 173.6 KB | ||
| 2020-11-24 07:00 |
201124_pr_transparency_debio_nl_final.pdf
|
Dutch | 176.9 KB | ||
| 2020-11-12 07:00 |
201111 Biocartis Q3 2020 Business Update_ENG_FINAL.pdf
|
English | 243.7 KB | ||
| 2020-11-12 07:00 |
201111 Biocartis Q3 2020 Business Update_NL_FINAL.pdf
|
Dutch | 263.1 KB | ||
| 2020-10-29 16:45 |
Biocartis and Exact Sciences Agree to End Collaboration Due to Changed Market …
|
English | 151.6 KB | ||
| 2020-10-29 16:45 |
Biocartis en Exact Sciences beëindigen samenwerking omwille van gewijzigde mar…
|
Dutch | 155.2 KB | ||
| 2020-10-29 08:30 |
Update on the partnership with Exact Sciences
|
English | 150.4 KB | ||
| 2020-10-29 08:30 |
Update over de samenwerking met Exact Sciences
|
Dutch | 152.9 KB | ||
| 2020-09-04 07:00 |
EGM 2020 Carens - Attendance form (DUT) (final).pdf
|
Dutch | 153.8 KB |
Automate Your Workflow. Get a real-time feed of all Biocartis Group NV filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biocartis Group NV
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biocartis Group NV via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-04-29 | Devogelaere Benoit | Executive member | Buy | 15,000 | N/A |
| 2021-04-28 | Marcofin BV | Executive member | Buy | 30,000 | N/A |
| 2021-04-27 | Herman Verrelst | Board | Buy | 60,000 | N/A |
| 2020-11-13 | Devogelaere Benoit | Executive member | Buy | 50,000 | N/A |
| 2020-05-06 | Herman Verrelst | Board | Buy | 50,000 | 249,625.00 EUR |
| 2020-05-06 | Herman Verrelst | Board | Buy | 300,000 | N/A |
| 2020-05-04 | Herman Verrelst | Board | Buy | 46,803 | 231,656.00 EUR |
| 2020-05-04 | Herman Verrelst | Board | Buy | 3,197 | 15,315.00 EUR |
| 2019-12-18 | Devogelaere Benoit | Executive member | Buy | 50,000 | N/A |
| 2019-12-16 | Welten Ewoud | Executive member | Buy | 10,000 | N/A |
Peer Companies
